Effectiveness of Noninvasive Fibrosis Markers for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B and Chronic Hepatitis B+D Induced Cirrhosis

Sahin, Tevfik Tolga; Serin, Ayfer; Emek, Ertan; Bozkurt, Birkan; Arikan, Bahadir Turkmen; Tokat, Yaman

doi:10.1016/j.transproceed.2019.01.193

Cited by 7 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean values of APRI and GAPRI at the end of treatment in both the naïve and experienced groups were below the cut-off values for significant fibrosis [9,10]. FIB-4, FORNS and the AP index obtained these values only in the naïve group [11,24,25]. It is noteworthy that the mean values of LSM (FibroScan) in each subgroup did not cross the border for insignificant fibrosis, which is 7.1 kPa [26].…”

Section: Discussionmentioning

confidence: 98%

“…At the start of treatment, when inflammation was the strongest, all the biomarkers strongly correlated with liver stiffness (FibroScan) and after 12 weeks of treatment this correlation decreased with the exception of the correlation with GAPRI, which increased. It is very satisfying that the value of tested non-invasive indirect markers of liver fibrosis after 12 weeks of treatment reached a value below the cut off for significant fibrosis, especially in the naïve group [9][10][11][12]24,25]. The mean values of APRI and GAPRI at the end of treatment in both the naïve and experienced groups were below the cut-off values for significant fibrosis [9,10].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Non-Invasive Indirect Markers of Liver Fibrosis after Interferon-Free Treatment for Hepatitis C

Przekop¹,

Klapaczyński

Grytczuk

et al. 2021

JCM

View full text Add to dashboard Cite

The effectiveness of interferon-free therapy during the course of HCV infection has already been confirmed. Liver fibrosis can be assessed in several ways, from biopsies to imaging tests. The present study evaluates the usefulness of non-invasive indirect biomarkers of liver fibrosis (APRI, GAPRI, FORNS, FIB-4, the AP index and HUI score) as markers of the effective treatment of HCV with the 3D regimen. Blood samples were collected from 70 patients suffering from chronic hepatitis C. Patients received the 3D AbbVie regimen for hepatitis C. All patients had HCV genotype 1b. The APRI, GAPRI, FIB-4, FORNS, HUI and AP index (age–platelet score) values were calculated with their respective algorithms. The stage of fibrosis was evaluated on the basis of a liver biopsy and confirmed by FibroScan-based transient elastography. An undetectable level of HCV RNA after 12 weeks of treatment with the 3D regimen indicates 100% eradication of hepatitis C virus. After the treatment, non-invasive indirect markers of liver fibrosis achieved levels below the limit for significant fibrosis, Thus, non-invasive indirect biomarkers of hepatic fibrosis failed to detect the presence of significant fibrosis, which was proved in histopathological examination. However, the eradication of hepatitis C virus by means of the 3D regimen treatment does not mean that patients were completely cured.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Non-Invasive Indirect Markers of Liver Fibrosis after Interferon-Free Treatment for Hepatitis C

Przekop¹,

Klapaczyński

Grytczuk

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Because of the occult attacks and high recurrence rate of HCC, the overall survival (OS) rate of HCC patients is unsatisfactory 2 . Despite the progress that has been made in screening and forecasting the prognosis of HCC, there is still a lack of reliable and simple biomarkers that can detect and monitor the prognosis of patients with HCC 3 …”

Section: Introductionmentioning

confidence: 99%

“…In some cancers such as gastrointestinal tumors, ovarian cancer, melanoma, urinary system tumors, lung cancer, and glioblastoma, CHI3L1 can help to distinguish patients between a good prognosis and poor prognosis 7 . Studies have shown that deficiency of CHI3LI can ameliorate liver fibrosis and that upregulation of CHI3L1 can exaggerate HCC cells proliferation, invasion, and migration 2,3 . It is promising that CHI3L1 can help to screen and monitor the prognosis of patients with HCC.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic value of serum Chitinase 3‐like protein 1 in hepatocellular carcinoma

Wang

Chen

Jin

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

The serum Chitinase 3‐like protein 1 (CHI3L1) protein level can distinguish the stages of liver fibrosis to a great extent. However, the diagnostic and prognostic significance of serum CHI3L1 in hepatocellular carcinoma (HCC) is not clarified. To evaluate the diagnostic and prognostic value of CHI3L1 in HCC, a total of 128 HCC patients treated in the HwaMei Hospital, University of Chinese Academy of Sciences, from December 2018 to April 2020 were collected retrospectively. Matched age and gender subjects, 40 patients with liver cirrhosis, 40 patients with chronic hepatitis, and 40 healthy subjects were enrolled in the control group. The relevant clinical laboratory and examination data and the overall survival time (OS) of the HCC patients were collected. The serum CHI3L1 expression level is related to α‐fetoprotein (AFP), tumor‐node‐metastasis (TNM) stage, maximum tumor diameter, liver cirrhosis, and HCC patient's OS (p < 0.05). The area under the curve (AUC) of CHI3L1 was 0.7875 with the cutoff value of 91.36 ng/ml. Combining the serum CHI3L1 and α‐fetoprotein (AFP) by a binary logistic regression model can increase the diagnostic sensitivity to 97.5%. Multivariate Cox regression analysis indicated that CHI3L1 is an independent prognostic factor in patients with HCC.

show abstract

“…Patients with chronic liver diseases are complicated with HCC, end-stage liver failure, and esophageal varices rupture [ 101 , 102 ]. While fibrosis indexes provide the prevalence of HCC in each fibrosis stage, tumor markers are superior to fibrosis indexes in the early detection of HCC [ 103 ]. For evaluating the loss of functional hepatic reserve, alternative noninvasive indexes including the Child–Pugh classification, albumin bilirubin grade, and MELD score are available [ 104 , 105 , 106 ].…”

Section: Revision Of the Idea “Liver Cirrhosis”mentioning

confidence: 99%

Serum Biomarkers of Liver Fibrosis Staging in the Era of the Concept “Compensated Advanced Chronic Liver Disease”

Fujita

Masaki

2021

JCM

View full text Add to dashboard Cite

Non-invasive indexes of liver fibrosis based on blood examinations have been developed for decades, partially replacing liver biopsy examinations. Recently, the concept of liver cirrhosis was revised and converted to “compensated advanced chronic liver diseases” since the Baveno VI consensus statement in 2015. The term “compensated advanced chronic liver diseases” was established based on the premise that serum biomarkers were not able to differentiate cirrhosis from severe fibrosis. The difficulty to histologically distinguish cirrhosis from severe fibrosis had been pointed out in 1977, when the definition and nomenclatures of cirrhosis had been determined by the World Health Organization. That was decades before serum biomarkers available at present were investigated. Though we are accustomed to differentiating the fibrosis stage as stage 1, 2, 3 (severe fibrosis), and 4 (cirrhosis), differentiation of cirrhosis from severe fibrosis is difficult even by histopathological examination. The current review will provide readers a framework to revise how to apply serum biomarkers on liver fibrosis staging in an era of the concept of “compensated advanced chronic liver disease”.

show abstract

Effectiveness of Noninvasive Fibrosis Markers for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B and Chronic Hepatitis B+D Induced Cirrhosis

Cited by 7 publications

References 18 publications

Non-Invasive Indirect Markers of Liver Fibrosis after Interferon-Free Treatment for Hepatitis C

Non-Invasive Indirect Markers of Liver Fibrosis after Interferon-Free Treatment for Hepatitis C

Diagnostic and prognostic value of serum Chitinase 3‐like protein 1 in hepatocellular carcinoma

Serum Biomarkers of Liver Fibrosis Staging in the Era of the Concept “Compensated Advanced Chronic Liver Disease”

Contact Info

Product

Resources

About